Evidence map›Paper›PMID 37004641›Full record

ArticleAdvances in therapy2023

Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis".

Jonathan Marshall, Akanksha Sharma, Patrick Darken, Mario Ouwens, Barinder Singh, Deniz Tansey-Dwyer

Open access · hybridAbstract readLetterCommentNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Jonathan MarshallAstraZeneca, Academy House, 136 Hills Road, Cambridge, CB2 8PA, UK. jonathan.marshall1@astrazeneca.com.
Akanksha SharmaPharmacoevidence, Mohali, PB, India.
Patrick DarkenAstraZeneca, Gaithersburg, MD, USA.
Mario OuwensAstraZeneca, Mölndal, Sweden.
Barinder SinghPharmacoevidence, Mohali, PB, India.
Deniz Tansey-DwyerAstraZeneca, Academy House, 136 Hills Road, Cambridge, CB2 8PA, UK.
AstraZeneca (United Kingdom) · GBAstraZeneca (Sweden) · SEAstraZeneca (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AndrostadienesPulmonary Disease, Chronic ObstructiveAdministration, InhalationBenzyl AlcoholsBronchodilator AgentsChlorobenzenesDrug CombinationsFluticasoneHumansQuinuclidinesAndrostadienesBenzyl AlcoholsBronchodilator AgentsChlorobenzenesDrug CombinationsFluticasonefluticasone furoateGSK573719QuinuclidinesvilanterolCOPDIndirect treatment comparisonNetwork meta-analysisTriple therapy

Identifiers

PMID37004641
PMCPMC10129921
OpenAlexW4362506969

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.